

Garetosmab

Cat. No.:	HY-P99632
CAS No.:	2097125-54-5
Target:	TGF- β Receptor
Pathway:	TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research ^[1] .
In Vitro	Garetosmab (REGN 2477) specifically binds to and blocks signaling of activin proteins containing the inhibin $\beta\alpha$ subunit (activins A, AB, and AC). In vitro, Garetosmab has high affinity and specificity for activins A, AB, and AC, but does not bind or functionally inhibit other TGF- β family ligands that share the same activin receptor pathways, including activin B, inhibin A, BMP-2, BMP6, BMP9, BMP10, GDF8, and GDF11 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Frédéric Vanhoutte, et al. Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study. J Clin Pharmacol. 2020 Nov;60(11):1424-1431.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA